Nancy Lurker

@EyePointPharma Executive Vice-Chair of the Board of Directors | Helping to create a life worth seeing. | Passion for elevating #WomenInBusiness. $EYPT

[Nancy Lurker @NancyLurker]

Thank you @KarenJagoda for having me on your latest Empowered Patient #podcast. I appreciated sharing more about EyePoint’s retina pipeline and the need for longer-acting, maintenance therapies across #WetAMD and #DiabeticRetinopathy – two diseases that can lead to blindness.

[EyePoint @EyePointPharma]

#NEWS - On the latest Empowered Patient #podcast, $EYPT @EyePointCEO shares #pipeline and #product updates, including the latest on #EYP1901, our sustained-delivery maintenance treatment being explored in #WetAMD and #NPDR.

🎧Listen here: https://t.co/Qc520w2WLv

#ophthotwitter

[Nancy Lurker @NancyLurker]

Thank you to Bloomberg Radio for having us on to share more about EyePoint and our new Northbridge manufacturing facility!

[EyePoint @EyePointPharma]

$EYPT News: @EyePointCEO and @DrJayDuker
share exciting updates on our new Northbridge manufacturing facility in the latest Bloomberg Baystate Business Hour podcast. Listen below 👇
https://t.co/kHVeSAsXtq

#Ophthalmology

[Nancy Lurker @NancyLurker]

A great day for EyePoint! We are delighted to announce that we’ve completed enrollment in our Phase 2 PAVIA clinical trial evaluating EYP-1901 as a potential nine-month treatment for NPDR. I’d like to thank our trial investigators, patients and internal team.

[EyePoint @EyePointPharma]

$EYPT announces completed enrollment in Phase 2 PAVIA #ClinicalTrial evaluating #EYP1901 as a potential 9-month treatment for #NPDR with 77 patients, exceeding the 60-patient target. Topline data is expected in 2Q 2024. Read more: https://t.co/wzHmHPoyal #OphthoTwitter #News

[Nancy Lurker @NancyLurker]

An exciting milestone for EyePoint as we increase our global manufacturing capabilities to support our expanding pipeline. Thank you to everyone who joined us to celebrate!

[EyePoint @EyePointPharma]

Last week, we celebrated a milestone in the making! We have officially broken ground for our Northbridge manufacturing facility. A groundbreaking celebration that represents an exciting future for the global manufacturing of #EYP1901. Thank you to all who came out to support.

[Nancy Lurker @NancyLurker]

Today we announced an important step forward for EyePoint with the sale of YUTIQ.

We are incredibly grateful to our commercial organization for their exceptional execution and dedication to bringing this product to patients.

Read more in the full announcement below.

[EyePoint @EyePointPharma]

#NEWS $EYPT announces sale of YUTIQ to Alimera Sciences, Inc. This strategic decision will enable us to focus on our lead product candidate, #EYP1901 and expanding our #retina #pipeline. Read the full release: https://t.co/nYKexEG2Pm

[Nancy Lurker @NancyLurker]

Thank you @NPetallides and @TDANetwork for having me on to share the latest on our business, pipeline and clinical trials. Check out the full interview below.

[Nancy Lurker @NancyLurker]

Thank you @BioTuesdays for the recent feature. Having the opportunity to discuss #EYPT1901 and our growing #pipeline is always a pleasure. Read more below.

[EyePoint @EyePointPharma]

🔊New #interview! In the latest @BioTuesdays feature, @EyePointCEO discusses EyePoint’s potentially long-lasting treatment for #WetAMD and #NPDR. Read the full interview: https://t.co/doyR8Bni08

#OphthoTwitter #news #treatment #eyecare #eyedisease

[Nancy Lurker @NancyLurker]

Thank you @TheVanguardNet for featuring me in the latest episode of your #podcast: “How to Engage Gen Z.” An important topic to discuss within the #ophthalmology space on how to leverage the younger generations. Listen below! 👇

[EyePoint @EyePointPharma]

🔊New #podcast! @EyePointCEO is featured in the latest episode of @TheVanguardNet podcast series "Real World Leadership" where she discusses how to engage with Gen Z. Listen here: https://t.co/fPRD2uovxY
#OphthoTwitter

[Nancy Lurker @NancyLurker]

Great things in the works at EyePoint! Thank you to The Wall Street Transcript for having me on to discuss our latest pipeline updates. Read the full interview below.

[EyePoint @EyePointPharma]

$EYPT News: @EyePointCEO featured in the latest Wall Street Transcript #interview. Read more on EyePoint’s latest #pipeline updates, #technology and strategic plans here:
https://t.co/F2HQr8GY7n
#OphthoTwitter #interview #news #strategy #biotech #ophthalmology

[Nancy Lurker @NancyLurker]

Thank you Dr. Joshua Mali and @healio_OSN for featuring me on the EyeCare Insider #podcast. I had a great time discussing the latest EyePoint #technology, #pipeline & #product updates.

Missed it? Listen to the full episode below.

[EyePoint @EyePointPharma]

On @Healio_OSN EyeCare Insider’s latest #podcast, @EyePointCEO discusses $EYPT #pipeline and #product updates, including the latest on #EYP1901, our sustained-delivery maintenance treatment being explored in #WetAMD and #DiabeticRetinopathy.

Listen here: https://t.co/4f0OzeTuKR

[Nancy Lurker @NancyLurker]

Last week, I had the honor of speaking at the @YPO New England Chapter as part of a presentation on Be the Change.

Supporting women on their career journeys is a passion of mine, & I joined an incredible group of women to discuss how we can all drive change across industries.

[EyePoint @EyePointPharma]

.@EyePointCEO Nancy Lurker recently spoke at @YPO’s New England Chapter about driving change to grow the number of women in C-suite roles. We are PROUD to be women led.

[Nancy Lurker @NancyLurker]

I couldn't fit all of this on Twitter, but wanted to make sure I share my appreciation with #OphthoTwitter, too.

💜🧡💜 Thank you for all you do!

[Nancy Lurker @NancyLurker]

Announcing an important milestone for EyePoint as we continue to advance our pipeline of innovative sustained delivery treatments for serious eye disorders! Originally designed to enroll 144 patients, the trial enrolled 160 total due to strong #investigator and #patient interest.

[EyePoint @EyePointPharma]

🎉#NEWS: EyePoint Pharmaceuticals completes enrollment for oversubscribed Phase 2 DAVIO 2 #clinicaltrial of #EYP1901 for maintenance treatment of #WetAMD.

Learn more: https://t.co/5SnOkURqT3

#clinicaltrials #ophthotwitter #ophthalmology #investornews

[Nancy Lurker @NancyLurker]

We have a powerhouse of a sales team and I am proud to witness their dedication to the patients we serve. I am looking forward to the great year we undoubtedly have ahead of us!

[EyePoint @EyePointPharma]

We’ve just wrapped our National Sales Meeting and have left with renewed vigor for our mission to develop solutions to help people facing serious eye disorders. Our days together provided us an opportunity to learn from one another and to deepen our retina knowledge.

[Nancy Lurker @NancyLurker]

The EyePoint team is showing up in force at #ARVO2023 with five presentations from April 23rd – 27th.

We look forward to presenting new preclinical data that highlights the potential of #vorolanib in #retinaldetachment as well as data from the #DAVIOTrial for #EYP-1901 and more.

[EyePoint @EyePointPharma]

$EYPT is proud to have a significant presence at #ARVO2023. We will be talking about the potential neuroprotective effect of tyrosine kinase inhibitor #vorolanib for #retinaldetachment, as well as new drugs, delivery systems and mechanisms of action in #WetAMD.

[Nancy Lurker @NancyLurker]

We are excited to begin this research collab & hope to leverage our Durasert technology to create a potential long-acting therapeutic for both Geographic Atrophy & Dry Macular Degeneration, where there remains significant unmet need for safe, effective & durable treatment options

[EyePoint @EyePointPharma]

#NEWS: $EYPT & RallyBio announce research collaboration to evaluate Rallybio’s inhibitor of complement C5 and EyePoint’s proprietary #Durasert technology for sustained intraocular delivery in #dryAMD & #GeographicAtrophy.

Learn more: https://t.co/QpozOb2KgD

[Nancy Lurker @NancyLurker]

Your commitment to patients is obvious to all. This honor is so well deserved. Congratulations, Jay! #TopDoc #TopDoctor

[EyePoint @EyePointPharma]

We’re thrilled to announce that EyePoint President & COO @DrJayDuker has been named as a @BostonMagazine 2023 top doctor! Anyone who has worked with Jay in his 30+ years of working to improve eyesight will agree, this honor is incredibly well deserved.
https://t.co/2pTLDiVes7

[Nancy Lurker @NancyLurker]

Exciting news! I am looking forward to this expansion that will positively impact the industry. This is a huge step for EyePoint and will support the global manufacturing of our top programs #EYP1901 and #YUTIQ.

#News

[Nancy Lurker @NancyLurker]

#OphthoTwitter, I'm excited to share this amazing news for our company! 🤩 @DrJayDuker has been promoted to President and COO of EyePoint.
Learn more below 👇
https://t.co/Z76kl6vvvF

[EyePoint @EyePointPharma]

We are thrilled to announce that our COO, @DrJayDuker has been promoted to President & COO! 🎉

Since joining $EYPT, he has been a tremendous asset to our organization as we make significant progress on our pipeline. https://t.co/bLZge4ddpz

#Ophthalmology #EyeNews #PharmaNews

[Nancy Lurker @NancyLurker]

From our @EyePointPharma team, #HappyHolidays! May your holiday season be filled with joy, health and happiness. 💜